RESEARCH TRIANGLE PARK, N.C., April 07, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene ...
Opus East LLC and Opus West Corp., two of the five independent operating companies of the Opus Group, have filed for bankruptcy protection to help liquidate their portfolios, according to parent ...
Opus Corporation, a developer headquartered in Minnetonka, Minn., filed for bankruptcy in three of its five regional operating companies. CEO Mark Rauenhorst said sharp declines in commercial real ...
Opus Genetics ( ($IRD) ) has shared an update. On December 17, 2025, Viatris Inc., the commercialization partner for Phentolamine Ophthalmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback